NASDAQ:TCRT Alaunos Therapeutics Q4 2025 Earnings Report $2.72 -0.03 (-1.09%) As of 02:02 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Alaunos Therapeutics EPS ResultsActual EPS-$0.36Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AAlaunos Therapeutics Revenue ResultsActual Revenue$0.00 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAlaunos Therapeutics Announcement DetailsQuarterQ4 2025Date3/31/2026TimeAfter Market ClosesConference Call DateTuesday, March 31, 2026Conference Call Time7:00AM ETUpcoming EarningsAlaunos Therapeutics' Q2 2026 earnings is estimated for Tuesday, August 18, 2026, based on past reporting schedules, with a conference call scheduled on Friday, August 14, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Alaunos Therapeutics Earnings HeadlinesAlaunos Therapeutics (NASDAQ:TCRT) Trading 8.9% Higher - Still a Buy?May 29, 2026 | americanbankingnews.comAlaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | finanznachrichten.deBefore you buy SpaceX shares, consider this alternative approachSpaceX has confidentially filed for an IPO with the SEC, targeting a June 2026 listing at a valuation exceeding $1.75 trillion - potentially the largest IPO in history. But one expert says buying shares directly may not be the smartest move. There is a lesser-known way to tap into this windfall that most investors haven't considered.June 3 at 1:00 AM | Weiss Ratings (Ad)Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markersMay 26, 2026 | msn.comAlaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse StudiesMay 26, 2026 | globenewswire.comAlaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity ModelsMay 18, 2026 | globenewswire.comSee More Alaunos Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Alaunos Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Alaunos Therapeutics and other key companies, straight to your email. Email Address About Alaunos TherapeuticsAlaunos Therapeutics (NASDAQ:TCRT), a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.View Alaunos Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Urban Outfitters Stock Stalls Despite Another Strong QuarterHIVE Earnings Highlight AI Ambitions Beyond Bitcoin MiningMongoDB Is the Latest SaaS Apocalypse Victim to Say "Not Today"Dollar General Signals Reversal With 60% Rebound PotentialKohl's Stock Soars After Better-Than-Feared QuarterCredo Technologies Paved a Path to a $300 Price PointFirstCash Turns Pawn Into a Growth Machine Upcoming Earnings Ciena (6/4/2026)Oracle (6/10/2026)Adobe (6/11/2026)Accenture (6/18/2026)FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
